Parameter
| Biomarker | TARC（CCL17） | Full name | Thymus and activation-regulated chemokine (C-C motif chemokine ligand 17) | Molecular Type | Protein (chemokines) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Treatment response monitoring, prognosis evaluation, and diagnostic triage. |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Blood and lymphoid tissue | Test Sample / Technology Platform | Serum/plasma (ELISA, electrochemical biosensors, Luminex) | ||
| Pathobiological Mechanisms | HRS cells secrete and recruit CCR4-positive immune cells, participating in tumor microenvironment regulation, with their levels decreasing after treatment. | ||||
| Clinical Availability Status | Clinical validation/partial application: Differentiation between patients with chronic Hodgkin lymphoma (cHL) and healthy individuals before treatment, with post-treatment levels correlating to event-free survival (EFS). | ||||
| Notes and Dynamics | The TARC level at the end of treatment in pediatric chronic lymphocytic leukemia (cHL) can be used to assess remission status; combining with EV-miRNA may improve predictive accuracy, and blocking its signaling pathway could become a therapeutic strategy. | ||||